RayKnowChina Research Map
Shortlist

ShanghaiFudan University

Huashan Hospital

复旦大学附属华山医院

Listed for 26 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Huashan Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌12 papers led
  2. Hepatocellular carcinoma肝细胞癌62 papers led1 open trial led
  3. Stomach cancer胃癌22 papers led6 open trials led
  4. Chordoma脊索瘤4 papers led
  5. Osteosarcoma骨肉瘤2 papers led
  6. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  7. Neuroblastoma神经母细胞瘤1 paper led
  8. Ewing sarcoma尤文肉瘤0 papers led
  9. Multiple myeloma多发性骨髓瘤5 papers led
  10. Haemophilia A血友病 A1 paper led
  11. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病23 papers led1 open trial led
  12. IgG4-related diseaseIgG4相关性疾病0 papers led
  13. Myasthenia gravis重症肌无力31 papers led4 open trials led
  14. Moyamoya disease烟雾病17 papers led
  15. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  16. Idiopathic pulmonary fibrosis特发性肺纤维化7 papers led
  17. Amyotrophic lateral sclerosis肌萎缩侧索硬化症10 papers led
  18. Spinal muscular atrophy脊髓性肌萎缩症11 papers led
  19. Pompe disease庞贝病1 paper led
  20. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  21. Behçet disease白塞病1 paper led
  22. IgA nephropathyIgA 肾病6 papers led
  23. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  24. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
  25. Inherited epidermolysis bullosa遗传性大疱性表皮松解症2 papers led
  26. Hereditary angioedema遗传性血管性水肿1 paper led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Fabry disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 12 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 5520232024: 2220242025: 332025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomicsImaging & AIImmunotherapy
Papers it led12
  1. The carcinogenesis of esophageal squamous cell cancer is positively regulated by USP13 through WISP1 deubiquitination.2025BioFactors (Oxford, England)
  2. The comprehensive oral microbiome landscape unveils its interplay with poor oral health in esophageal squamous cell carcinoma risk.2025Cell reports. MedicineFree full text
  3. Cancer-associated fibroblasts promote growth and dissemination of esophageal squamous cell carcinoma cells by secreting WNT family member 5A.2025Molecular and cellular biochemistry
  4. Metabolism score and machine learning models for the prediction of esophageal squamous cell carcinoma progression.2024Cancer scienceFree full text
  5. Rad51 and Systemic Inflammatory Indicators as Novel Prognostic Markers in Esophageal Squamous Cell Carcinoma.2024Technology in cancer research & treatmentFree full text
  6. Reconstruction using the colon or jejunum in patients with synchronous advanced esophageal and gastric cancers: a retrospective study from a single institutional database.2023BMC surgeryFree full text
  7. Dasabuvir suppresses esophageal squamous cell carcinoma growth in vitro and in vivo through targeting ROCK1.2023Cell death & diseaseFree full text
  8. Single-cell sequencing of multi-region resolves geospatial architecture and therapeutic target of endothelial cells in esophageal squamous cell carcinoma.2023Clinical and translational medicineFree full text
  9. Grading criteria for venous invasion in thoracic esophageal squamous cell carcinoma.2023Journal of cardiothoracic surgeryFree full text
  10. ESRRG-PKM2 axis reprograms metabolism to suppress esophageal squamous carcinoma progression and enhance anti-PD-1 therapy efficacy.2023Journal of translational medicineFree full text
  11. The prognostic value of separate lymphatic invasion and vascular invasion in oesophageal squamous cell carcinoma: a meta-analysis and systematic review.2022BMC cancerFree full text
  12. Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.2022Neoplasma
More papers found outside PubMed (not counted)9
  1. 148P Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial2024Immuno-Oncology Technologyarticle
  2. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  3. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  4. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  5. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  6. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  7. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  8. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  9. Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.2022Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 62 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
62
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 8820212022: 171720222023: 8820232024: 161620242025: 12122025

15 hospitals in Shanghai for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
    Phase
    N/A
    Started
    2025-12
    Registry
    NCT07268131

    Age 18 years to 75 years (registered criteria)

    Led by Huashan HospitalShanghai

  2. Recruiting
    Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
    Phase
    Phase 2
    Started
    2025-11
    Registry
    NCT07331883

    Age 18 years to 75 years (registered criteria)

    Led by Ruijin Hospital; 2 listed hospitals as study sitesChangchun, Shanghai

  3. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatology
Papers it led62
  1. A Predictive Model Study on Differentiating Intrahepatic Cholangiocarcinoma From Hepatocellular Carcinoma Using Contrast-Enhanced Ultrasound, Shear Wave Elastography, and Clinical Feature-Based Nomogram.2026Journal of clinical ultrasound : JCU
  2. Activatable Sulfur Dioxide Nanosonosensitizer Enables Precisely Controllable Sono-Gaseous Checkpoint Trimodal Therapy for Orthotopic Hepatocellular Carcinoma.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients.2025Antiviral research
  4. Nanomedicine-unlocked radiofrequency dynamic therapy dampens incomplete radiofrequency ablation-arised immunosuppression to suppress cancer relapse.2025Biomaterials
  5. Comparison of 11C-Acetate and 18F-FDG PET/CT for Immune Infiltration and Prognosis in Hepatocellular Carcinoma.2025Cancer scienceFree full text
  6. Population stratification using MASLD polygenic risk score improves severe liver disease prediction by clinical fibrosis scores.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  7. Prognostic and diagnostic value of [18F]FDG, 11C-acetate, and [68Ga]Ga-FAPI-04 PET/CT for hepatocellular carcinoma.2025European radiology
  8. A novel nomogram to predict the recurrence of hepatocellular carcinoma after liver transplantation using extended selection criteria.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  9. Adjuvant lenvatinib in combination with transarterial chemoembolization for hepatocellular carcinoma patients with high risk of postoperative recurrence: A multicenter prospective cohort study.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  10. Integrated Genetic Information of Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Traits Improves Hepatocellular Carcinoma Risk Stratification and Screening.2025JCO precision oncology
  11. HBV sequence integrated to enhancer acting as oncogenic driver epigenetically promotes hepatocellular carcinoma development.2025Journal of experimental & clinical cancer research : CRFree full text
  12. Cholesterol suppresses AMFR-mediated PDL1 ubiquitination and degradation in HCC.2025Molecular and cellular biochemistryFree full text
  13. Transforming acidic coiled-coil-containing protein 3-mediated lipid metabolism reprogramming impairs CD8+ T-cell cytotoxicity in hepatocellular carcinoma.2025Signal transduction and targeted therapyFree full text
  14. The Absence of Intra-Tumoral Tertiary Lymphoid Structures is Associated with a Worse Prognosis and mTOR Signaling Activation in Hepatocellular Carcinoma with Liver Transplantation: A Multicenter Retrospective Study.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  15. Deciphering the role of KLRB1: a novel prognostic indicator in hepatocellular carcinoma.2024BMC gastroenterologyFree full text
  16. Cross-institutional evaluation of deep learning and radiomics models in predicting microvascular invasion in hepatocellular carcinoma: validity, robustness, and ultrasound modality efficacy comparison.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  17. Acetyl-CoA metabolic accumulation promotes hepatocellular carcinoma metastasis via enhancing CXCL1-dependent infiltration of tumor-associated neutrophils.2024Cancer letters
  18. Circular RNA circESYT2 serves as a microRNA-665 sponge to promote the progression of hepatocellular carcinoma through ENO2.2024Cancer scienceFree full text
  19. ASB3 promotes hepatocellular carcinoma progression by mediating DR5 ubiquitination in TRAIL resistance.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  20. Targeting Gsk3a reverses immune evasion to enhance immunotherapy in hepatocellular carcinoma.2024Journal for immunotherapy of cancerFree full text
  21. Integration of single-cell and spatial transcriptome sequencing identifies CDKN2A as a senescent biomarker in endothelial cells implicating hepatocellular carcinoma malignancy.2024Journal of cancer research and clinical oncologyFree full text
  22. Immune- and metabolism-related gene signature analysis uncovers the prognostic and immune microenvironments of hepatocellular carcinoma.2024Journal of cancer research and clinical oncologyFree full text
  23. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives.2024Journal of hematology & oncologyFree full text
  24. Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma.2024Journal of medicinal chemistry
  25. Preoperative Ultrasound Radomics to Predict Posthepatectomy Liver Failure in Patients With Hepatocellular Carcinoma.2024Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  26. Stomatin-like protein 2 promotes cell proliferation and survival under 5-Fluorouracil stress in hepatocellular carcinoma.2024Molecular biology reports
  27. Automatic segmentation of hepatocellular carcinoma on dynamic contrast-enhanced MRI based on deep learning.2024Physics in medicine and biology
  28. Nuclear translocation of metabolic enzyme PKM2 participates in high glucose-promoted HCC metastasis by strengthening immunosuppressive environment.2024Redox biologyFree full text
  29. Nomogram based on liver stiffness and spleen area with ultrasound for posthepatectomy liver failure: A multicenter study.2024World journal of gastroenterologyFree full text
  30. Spleen to non-cancerous liver volume ratio predicts liver cirrhosis in hepatocellular carcinoma patients.2023Abdominal radiology (New York)RCT
  31. SREBP2 inhibitor betulin sensitizes hepatocellular carcinoma to lenvatinib by inhibiting the mTOR/IL-1β pathway.2023Acta biochimica et biophysica SinicaFree full text
  32. Fusing Positive and Negative CT Contrast Nanoagent for the Sensitive Detection of Hepatoma.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  33. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.2023European journal of internal medicine
  34. The m6A-related gene signature stratifies poor prognosis patients and characterizes immunosuppressive microenvironment in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  35. The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma.2023Hepatobiliary & pancreatic diseases international : HBPD INT
  36. An Angiogenic Gene Signature for Prediction of the Prognosis and Therapeutic Responses of Hepatocellular Carcinoma.2023International journal of molecular sciencesFree full text
  37. CircularRNA Hsa_circ_0093335 promotes hepatocellular carcinoma progression via sponging miR-338-5p.2023Journal of cellular and molecular medicineFree full text
  38. Alcohol consumption and hepatocellular carcinoma: novel insights from a prospective cohort study and nonlinear Mendelian randomization analysis.2022BMC medicineFree full text
  39. Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.2022Cancer researchFree full text
  40. 27-Hydroxycholesterol promotes metastasis by SULT2A1-dependent alteration in hepatocellular carcinoma.2022Cancer scienceFree full text
  41. Cholesterol suppresses GOLM1-dependent selective autophagy of RTKs in hepatocellular carcinoma.2022Cell reports
  42. The combination of PD-1 blockade with interferon-α has a synergistic effect on hepatocellular carcinoma.2022Cellular & molecular immunologyFree full text
  43. LncRNA GASAL1 promotes hepatocellular carcinoma progression by up-regulating USP10-stabilized PCNA.2022Experimental cell research
  44. Rapamycin enhances the anti-tumor activity of cabozantinib in cMet inhibitor-resistant hepatocellular carcinoma.2022Frontiers of medicine
  45. Significance of Identifying Key Genes Involved in HBV-Related Hepatocellular Carcinoma for Primary Care Surveillance of Patients with Cirrhosis.2022GenesFree full text
  46. Immunotherapy for hepatobiliary malignancies: Progress and prospective.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  47. Strategies for improving the efficacy of immunotherapy in hepatocellular carcinoma.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  48. Biomarkers for response to immunotherapy in hepatobiliary malignancies.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  49. Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.2022Journal of hepatology
  50. Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study.2022Journal of medical virologyFree full text
  51. RNF4 silencing induces cell growth arrest and DNA damage by promoting nuclear targeting of p62 in hepatocellular carcinoma.2022Oncogene
  52. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.2022PeerJFree full text
  53. Predictive Value of Platelet-Related Measures in Patients with Hepatocellular Carcinoma.2022Technology in cancer research & treatmentFree full text
  54. Radiomics for the detection of microvascular invasion in hepatocellular carcinoma.2022World journal of gastroenterologyFree full text
  55. Integrated bioinformatics analysis revealed the regulation of angiogenesis by tumor cells in hepatocellular carcinoma.2021Bioscience reportsFree full text
  56. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.2021Cancer investigation
  57. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.2021Hepatology (Baltimore, Md.)
  58. S100 calcium-binding protein A9 from tumor-associated macrophage enhances cancer stem cell-like properties of hepatocellular carcinoma.2021International journal of cancer
  59. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.2021Journal of hematology & oncologyFree full text
  60. Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1): A Novel Predictor for Recurrence of Hepatocellular Carcinoma After Curative Resection.2021Medical science monitor : international medical journal of experimental and clinical researchFree full text
  61. GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages.2021Signal transduction and targeted therapyFree full text
  62. Exosomal S100A4 derived from highly metastatic hepatocellular carcinoma cells promotes metastasis by activating STAT3.2021Signal transduction and targeted therapyFree full text
All its trials on ClinicalTrials.gov, any status12
  1. A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular CarcinomaStatus unknownNCT06148155Lead sponsorN/AStart 2023-06
  2. Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular CarcinomaStatus unknownNCT05105815Lead sponsorEarly phase 1Start 2021-12
  3. The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by ResectionStatus unknownNCT03253250Lead sponsorPhase 4Start 2017-09
  4. TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan CriteriaRecruitingNCT07268131Lead (inferred)N/AStart 2025-12
  5. PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCCStatus unknownNCT04974281Lead (inferred)Early phase 1Start 2021-01
  6. Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaStatus unknownNCT03838796Lead (inferred)N/AStart 2019-01
  7. Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular CarcinomaTerminatedNCT02748304Lead (inferred)N/AStart 2016-04
  8. Laparoscopic Versus Open Liver Resection for Hepatocellular CarcinomaStatus unknownNCT02526043Lead (inferred)N/AStart 2015-08
  9. Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)RecruitingNCT07331883Study sitePhase 2Start 2025-11
  10. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early DiagnosisRecruitingNCT06822413Study siteStart 2022-09
  11. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)CompletedNCT04740307Study sitePhase 2Start 2021-03
  12. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 22 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
22
2021–2025
Trials led
9
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 5520232024: 4420242025: 442025

18 hospitals in Shanghai for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic Cancer
    Phase
    Early phase 1
    Started
    2026-06
    Registry
    NCT07707531

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  2. Recruiting
    A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique
    Phase
    N/A
    Started
    2024-01
    Registry
    NCT06300879

    Age 18 years to 75 years (registered criteria)

    Led by Huashan HospitalShanghai

  3. Recruiting
    Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled Study
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06679244

    Age 18 years to 80 years (registered criteria)

    Led by Huashan Hospital; 2 listed hospitals as study sitesShanghai

  4. Recruiting
    Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2023-10
    Registry
    NCT06054906

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  5. Not yet recruiting
    Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06759233

    Age 18 years to 80 years (registered criteria)

    Led by Huashan HospitalShanghai

  6. Not yet recruiting
    A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2025-05
    Registry
    NCT06957977

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  7. Recruiting
    Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT06822413

    Age not stated (registered criteria)

    Led by Second Affiliated Hospital, Zhejiang University; 3 listed hospitals as study sitesHangzhou, Nanchang, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgeryPeritoneal spread & advanced diseaseNutrition & recovery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicineMedical oncology
Papers it led22
  1. Neuroactive ligand-receptor interaction in gastric cancer: a comprehensive spatial single-cell analysis.2026Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  2. Application of Hao's Esophagogastrostomy by Fissure Technique (HEFT) in proximal gastrectomy: protocol for a prospective, multicentre, randomised controlled study.2025BMJ openFree full text
  3. Spatiotemporal Correlation Analysis for the Incidence of Esophageal and Gastric Cancer From 2010 to 2019: Ecological Study.2025JMIR cancerFree full text
  4. Shortcoming of ypStage staging system: Lack of differentiation for preoperative treatment.2025PloS oneFree full text
  5. A novel anti-reflux esophagogastric anastomosis in totally laparoscopic proximal gastrectomy: Hao's esophagogastrostomy by fissure technique (HEFT).2025World journal of surgical oncologyFree full text
  6. Circular RNA hsa_circ_0004650 Enhances 5-Fluorouracil Resistance in Gastric Cancer via Sponging miR-145-5p.2024Anticancer research
  7. Elucidating epigenetic landscape of gastric premalignant lesions through genome-wide mapping of 5-hydroxymethylcytosines: A 12-year median follow-up study.2024Clinical and translational medicineFree full text
  8. The safety and feasibility assessment of overlap esophagojejunostomy with self-pulling and latter transection technique in totally laparoscopic total gastrectomy.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  9. New purse-string suture clamp and multi-functional seal cap: a simple intracorporeal circular-stapled oesophagojejunostomy after laparoscopic total gastrectomy.2024Langenbeck's archives of surgery
  10. Reconstruction using the colon or jejunum in patients with synchronous advanced esophageal and gastric cancers: a retrospective study from a single institutional database.2023BMC surgeryFree full text
  11. Identification of three lncRNA-related prognostic signatures in gastric cancer by integrated multi-omics analysis.2023Epigenomics
  12. The global, regional, and national burden of stomach cancer among adolescents and young adults in 204 countries and territories, 1990-2019: A population-based study.2023Frontiers in public healthFree full text
  13. Systematic single-cell dissecting reveals heterogeneous oncofetal reprogramming in the tumor microenvironment of gastric cancer.2023Human cell
  14. Screening and Bioinformatics Analyses of Key miRNAs Associated with Toll-like Receptor Activation in Gastric Cancer Cells.2023Medicina (Kaunas, Lithuania)Free full text
  15. Exosome-mediated transfer of circ_0063526 enhances cisplatin resistance in gastric cancer cells via regulating miR-449a/SHMT2 axis.2022Anti-cancer drugs
  16. Effect of different oesophagojejunostomy methods on the quality of life of gastric cancer patients after totally laparoscopic total gastrectomy with self-pulling and latter transected technique: study protocol for a randomised trial.2022BMJ openFree full text
  17. Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study.2022European journal of nuclear medicine and molecular imaging
  18. Bracket-like suture method: a novel, circular marked, simplest sided purse-string suture technique for intracorporeal circular-stapled oesophagojejunostomy during laparoscopic total gastrectomy.2022Langenbeck's archives of surgery
  19. The regulation of hsacirc_004413 promotes proliferation and drug resistance of gastric cancer cells by acting as a competing endogenous RNA for miR-145-5p.2022PeerJFree full text
  20. LINC00511 promotes gastric cancer progression by regulating SOX4 and epigenetically repressing PTEN to activate PI3K/AKT pathway.2021Journal of cellular and molecular medicineFree full text
  21. Handover method: Simple, classic and harmonized intracorporeal closure of stapled duodenal stump during laparoscopic gastrectomy.2021Journal of surgical oncology
  22. The safety and feasibility of intra-corporeal gastroduodenostomy using a self-pulling and latter transected method (Delta SPLT) in totally laparoscopic distal gastrectomy.2021Journal of surgical oncology
Chinese-language papers (not in the count)2
  1. [A novel exploration of circular-stapled esophagojejunostomy in totally laparoscopic total gastrectomy: purse-string suture device with multi-functional seal cap].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Laparoscopic circular stapled gastrointestinal anastomosis using novel device of sealed cap access after total laparoscopic gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status11
  1. A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled IR199 in Patients With Gastric Cancer and Pancreatic CancerRecruitingNCT07707531Lead sponsorEarly phase 1Start 2026-06
  2. Application of a New Surgical Technique in Proximal Gastrectomy: a Prospective, Multicenter Randomized Controlled StudyRecruitingNCT06679244Lead sponsorN/AStart 2024-12
  3. A Prospective Study on Esophagogastrostomy by an Innovative Surgical TechniqueRecruitingNCT06300879Lead sponsorN/AStart 2024-01
  4. Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric CancerRecruitingNCT06054906Lead sponsorPhase 2Start 2023-10
  5. Metronomic Chemotherapy in Advanced Gastric CancerStatus unknownNCT02855788Lead sponsorPhase 2Start 2015-05
  6. Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric CancerNot yet recruitingNCT06759233Lead (inferred)Phase 2Start 2025-05
  7. A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric CancerNot yet recruitingNCT06957977Lead (inferred)Phase 2Start 2025-05
  8. Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic CancerStatus unknownNCT06203613Lead (inferred)N/AStart 2023-12
  9. The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant AscitesStatus unknownNCT02779608Lead (inferred)Phase 2Start 2017-01
  10. Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early DiagnosisRecruitingNCT06822413Study siteStart 2022-09
  11. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 4 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 3.8%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 1120242025: 002025

15 hospitals in Shanghai for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

60 hospitals in Shanghai for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

21 hospitals in Shanghai for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. The influence of marital status on the survival of patients with operable gastrointestinal stromal tumor: A SEER-based study.2019The International journal of health planning and management

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

34 hospitals in Shanghai for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

15 hospitals in Shanghai for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study.2020Journal of orthopaedic surgery and research

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 5 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.3%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 2220242025: 002025

16 hospitals in Shanghai for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & riskKidney & bone complications
Departments in papersNeurosurgeryPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Shanghai for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 23 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 4.7%.

Papers led
23
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 7720222023: 3320232024: 2220242025: 882025

4 hospitals in Shanghai for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    HANDLE-a Real World Study on Satralizumab in NMOSD
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT06829524

    Age 12 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisBiologic drugsRelapse prevention
Departments in papersNeurologyPathology / laboratory medicineRadiology / nuclear medicine
Papers it led23
  1. Concomitant Sjögren's disease in patients with NMOSD: impacts on neurologic disease severity and recurrence.2025Arthritis research & therapyFree full text
  2. Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab.2025Autoimmunity reviews
  3. Outcomes and predictors of relapse and severe pneumonia in Chinese patients with AQP4-IgG-positive neuromyelitis optica spectrum disorder receiving inebilizumab: a prospective cohort study.2025Frontiers in immunologyFree full text
  4. Dysregulated Tfh/B cells and their interactions in neuromyelitis optica spectrum disorder.2025Frontiers in immunologyFree full text
  5. Eculizumab for the acute attack of neuromyelitis optica spectrum disorder.2025Frontiers in immunologyFree full text
  6. Comparison of the clinical and laboratory characteristics of neuromyelitis optica spectrum disorder with or without cerebrospinal fluid oligoclonal bands: a cohort with 36-month follow-up.2025Frontiers in immunologyFree full text
  7. Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis optica spectrum disorder.2025Journal of neurology
  8. KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort.2025Journal of neurology, neurosurgery, and psychiatry
  9. First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders.2024CNS neuroscience & therapeuticsFree full text
  10. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.2024European radiology
  11. Causal associations between prodromal infection and neuromyelitis optica spectrum disorder: A Mendelian randomization study.2023European journal of neurology
  12. Clinical feature and disease outcome in patients with myelin oligodendrocyte glycoprotein antibody-associated disorder: a Chinese study.2023Journal of neurology, neurosurgery, and psychiatry
  13. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab.2023Neurology(R) neuroimmunology & neuroinflammationFree full text
  14. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.2022European journal of neurology
  15. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.2022European journal of neurology
  16. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.2022Frontiers in immunologyFree full text
  17. Analysis of Pregnancy-Related Attacks in Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Meta-Analysis.2022JAMA network openFree full text
  18. The description of neuromyelitis optica spectrum disorder: Patient registry in Yangtze River Delta area of China.2022Multiple sclerosis and related disorders
  19. Longitudinal evaluation of clinical characteristics of Chinese neuromyelitis optica spectrum disorder patients with different AQP4-IgG serostatus.2022Multiple sclerosis and related disorders
  20. Efficacy and safety of rehabilitation exercise in neuromyelitis optica spectrum disorder during the acute phase: A prospective cohort study.2022Multiple sclerosis and related disorders
  21. Myelitis in inflammatory disorders associated with myelin oligodendrocyte glycoprotein antibody and aquaporin-4 antibody: A comparative study in Chinese Han patients.2021European journal of neurology
  22. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.2021Frontiers in immunologyFree full text
  23. Low-dose tacrolimus in treating neuromyelitis optica spectrum disorder.2021Multiple sclerosis and related disorders
All its trials on ClinicalTrials.gov, any status4
  1. HANDLE-a Real World Study on Satralizumab in NMOSDRecruitingNCT06829524Lead sponsorStart 2025-03
  2. BLAZE-Limiting Approach in NMOSDCompletedNCT06888622Lead sponsorStart 2023-10
  3. An Open Label Study of the Effects of SHR1459 in NMOSDs PatientsCompletedNCT04670770Study sitePhase 2Start 2021-01
  4. A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersCompletedNCT04146285Study sitePhase 1Start 2020-09
More papers found outside PubMed (not counted)5
  1. B-103 KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort2025Clinical Chemistryconference-abstract
  2. Satralizumab Treatment in Chinese Patients with AQP4-ab-positive Neuromyelitis Optica Specturm Disorder: A Prospective Study (P9-1.015)2025Neurologyarticle
  3. The effect of health-related hardiness education in patients with neuromyelitis optica spectrum disorders2023Research Squarepreprint
  4. Neuromyelitis optica spectrum disorders and pregnancy2022DOAJ (DOAJ: Directory of Open Access Journals)article
  5. Is low threshold of B cells an obligatory monitoring indicator of repeated RTX infusion in the treatment of Neuromyelitis Optica spectrum disorder? – A report of two cases2021Neuroimmunology Reportsarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led no English-language PubMed papers on IgG4-related disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Shanghai for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 31 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 6.2%.

Papers led
31
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
4
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 4420212022: 8820222023: 3320232024: 5520242025: 992025

7 hospitals in Shanghai for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT04535843

    Age 0 years to 90 years (registered criteria)

    Led by Huashan Hospital; 1 listed hospital as study siteShanghai

  2. Recruiting
    Myasthenia Gravis Registry in China
    Phase
    Not given
    Started
    2024-02
    Registry
    NCT06241521

    Age not stated (registered criteria)

    Led by Huashan Hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Nanchang, Shanghai, Suzhou, Tianjin, Xi'an, Xuzhou, Zhengzhou

  3. Recruiting
    Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
    Phase
    Not given
    Started
    2023-08
    Registry
    NCT07146425

    Age 18 years to Not stated (registered criteria)

    Led by Huashan HospitalShanghai

  4. Not yet recruiting
    An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06759948

    Age 18 years to 75 years (registered criteria)

    Led by Huashan HospitalShanghai

  5. Recruiting
    A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07622342

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Shanghai

  6. Recruiting
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
    Phase
    Phase 1
    Started
    2025-09
    Registry
    NCT07215650

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Guiyang, Shanghai, Taiyuan, Tianjin, Zhengzhou

  7. Recruiting
    A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06447597

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Wuhan, Xi'an

  8. Recruiting
    Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06463587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou, Zunyi

  9. Recruiting
    Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
    Phase
    Phase 2
    Started
    2022-07
    Registry
    NCT05067348

    Age 18 years to 80 years (registered criteria)

    Led by Tangdu Hospital; 5 listed hospitals as study sitesBeijing, Changsha, Chengdu, Shanghai, Tianjin, Xi'an

  10. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

  11. Not yet recruiting
    An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2026-09
    Registry
    NCT07818291

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisBiologic & complement drugsCrisis & intensive care
Departments in papersNeurology
Papers it led31
  1. In-Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis.2026Annals of clinical and translational neurologyFree full text
  2. Eculizumab as a new option for perioperative treatment in thymoma-associated myasthenia gravis.2026Clinical immunology (Orlando, Fla.)
  3. Interleukin-6 in neuroimmunological disorders: Pathophysiology and therapeutic advances with satralizumab.2025Autoimmunity reviews
  4. Association of blocking acetylcholine receptor antibodies with clinical subtypes and disease severity in myasthenia gravis.2025Clinica chimica acta; international journal of clinical chemistry
  5. Efgartigimod versus standard of care in new-Onset AChR subtype generalized myasthenia gravis: A prospective cohort study.2025Clinical immunology (Orlando, Fla.)
  6. Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment.2025Frontiers in immunologyFree full text
  7. Serum cystatin C as a potential biomarker for generalized acetylcholine receptor antibody-positive myasthenia gravis.2025Frontiers in immunologyFree full text
  8. Distal muscle weakness as the main onset symptom in thymoma-associated myasthenia gravis: a case report and literature review.2025Frontiers in immunologyFree full text
  9. Clinical outcome and peripheral CD4+ T profile in impending myasthenic crisis: A prospective cohort study.2025Journal of neuroimmunology
  10. Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series.2025Journal of neuroimmunology
  11. The Etiology Analysis of Myasthenia Gravis with In-Hospital Mortality in the Neurocritical Care Unit.2025Neurocritical care
  12. Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China.2024Annals of clinical and translational neurologyFree full text
  13. A predictive nomogram for short-term outcomes of myasthenia gravis patients treated with low-dose rituximab.2024CNS neuroscience & therapeuticsFree full text
  14. Clinical outcome and peripheral immune profile of myasthenic crisis with omicron infections: A prospective cohort study.2024Clinical immunology (Orlando, Fla.)
  15. Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series.2024Frontiers in immunologyFree full text
  16. Nomogram for predicting pregnancy-related relapse of myasthenia gravis.2024Orphanet journal of rare diseasesFree full text
  17. Autoantibody levels as biomarkers of disease activity in the management of myasthenia gravis.2023European journal of neurology
  18. Peripheral immune landscape for hypercytokinemia in myasthenic crisis utilizing single-cell transcriptomics.2023Journal of translational medicineFree full text
  19. Myasthenic crisis in thymoma-associated myasthenia gravis: a multicenter retrospective cohort study.2023Neuromuscular disorders : NMD
  20. Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis.2022BMC immunologyFree full text
  21. Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: A prospective cohort study.2022Clinical immunology (Orlando, Fla.)
  22. Pneumonia in myasthenia gravis: Microbial etiology and clinical management.2022Frontiers in cellular and infection microbiologyFree full text
  23. Herpesvirus entry mediator on T cells as a protective factor for myasthenia gravis: A Mendelian randomization study.2022Frontiers in immunologyFree full text
  24. A Targeted Complement Inhibitor CRIg/FH Protects Against Experimental Autoimmune Myasthenia Gravis in Rats via Immune Modulation.2022Frontiers in immunologyFree full text
  25. Berberine attenuates experimental autoimmune myasthenia gravis via rebalancing the T cell subsets.2022Journal of neuroimmunology
  26. Pneumonia and systemic inflammatory response syndrome as predictors for difficult-/prolonged-weaning after invasive ventilation in myasthenic crisis: A retrospective analysis of a Chinese cohort.2022Neuromuscular disorders : NMD
  27. Risk factors for pregnancy-related clinical outcome in myasthenia gravis: a systemic review and meta-analysis.2022Orphanet journal of rare diseasesFree full text
  28. In-depth peripheral CD4+ T profile correlates with myasthenic crisis.2021Annals of clinical and translational neurologyFree full text
  29. The role of innate immunity in myasthenia gravis.2021Autoimmunity reviews
  30. Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis.2021Journal of translational medicineFree full text
  31. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.2021Muscle & nerve
All its trials on ClinicalTrials.gov, any status24
  1. Myasthenia Gravis Registry in ChinaRecruitingNCT06241521Lead sponsorStart 2024-02
  2. Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in ChinaRecruitingNCT04535843Lead sponsorStart 2024-02
  3. Construction of A Multimodal Digital Assessment Model for Myasthenia GravisRecruitingNCT07146425Lead sponsorStart 2023-08
  4. Study of Myasthenic Crisis in ChinaStatus unknownNCT04837625Lead sponsorStart 2020-10
  5. Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot StudyCompletedNCT04431895Lead sponsorEarly phase 1Start 2020-06
  6. An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia GravisNot yet recruitingNCT06759948Lead (inferred)Phase 1Start 2025-02
  7. An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia GravisNot yet recruitingNCT07818291Study sitePhase 1Start 2026-09
  8. A Phase II Study of SHR-2173 Injection in Patients With Myasthenia GravisRecruitingNCT07622342Study sitePhase 2Start 2026-08
  9. Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)RecruitingNCT07215650Study sitePhase 1Start 2025-09
  10. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Study sitePhase 2/Phase 3Start 2024-07
  11. Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RecruitingNCT06463587Study sitePhase 3Start 2024-06
  12. Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia GravisRecruitingNCT05067348Study sitePhase 2Start 2022-07
  13. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  14. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Active, not recruitingNCT06456580Study sitePhase 3Start 2024-07
  15. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Study sitePhase 3Start 2024-04
  16. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisActive, not recruitingNCT06558279Study sitePhase 3Start 2024-09
  17. Open-Label Extension of Tocilizumab in Subjects With Generalized Myasthenia GravisStatus unknownNCT05716035Study sitePhase 2/Phase 3Start 2023-04
  18. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03
  19. Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia GravisCompletedNCT05332210Study sitePhase 3Start 2022-06
  20. A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisTerminatedNCT04963270Study sitePhase 3Start 2021-10
  21. Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG PatientsCompletedNCT05039190Study sitePhase 3Start 2021-09
  22. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisActive, not recruitingNCT05070858Study sitePhase 3Start 2021-12
  23. A Study to Evaluate the Efficacy, Safety and PD and PK of HBM9161 in MG PatientsCompletedNCT04346888Study sitePhase 2Start 2020-07
  24. A Study of TACI(Transmembrane Activator and Calcium-modulator and Cyclophilin Ligand (CAML) Interactor)-Antibody Fusion Protein Injection (RC18) in Subjects With Systemic Myasthenia GravisCompletedNCT04302103Study sitePhase 2Start 2020-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 17 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 4.8%.

Papers led
17
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 4420212022: 4420222023: 4420232024: 1120242025: 442025

4 hospitals in Shanghai for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

  2. Recruiting
    Registry of Multicenter Brain-Heart Comorbidity in China
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT05961748

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 4 listed hospitals as study sitesBeijing, Harbin, Shanghai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & blood flowRevascularisation surgeryStroke & bleeding outcomes
Departments in papersNeurosurgery
Papers it led17
  1. Non-Invasive Diagnosis of Moyamoya Disease Using Serum Metabolic Fingerprints and Machine Learning.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Inhalational versus intravenous anesthetic for cerebrovascular accident outcomes after surgical revascularization for adult moyamoya disease.2025BMC anesthesiologyFree full text
  3. The cerebellar glucose metabolism in moyamoya vasculopathy and its correlation with neurocognitive performance after cerebral revascularization surgery: a [18F]FDG PET study.2025European journal of nuclear medicine and molecular imagingFree full text
  4. In-depth cerebrovascular lipidomics profiling for discovering novel biomarkers and mechanisms in moyamoya and intracranial atherosclerotic disease.2025International journal of surgery (London, England)Free full text
  5. Individualised evaluation based on pathophysiology for moyamoya vasculopathy: application in surgical revascularisation.2024Stroke and vascular neurologyFree full text
  6. How I do it: direct pressure measurement in moyamoya bypass.2023Acta neurochirurgica
  7. Brain perfusion, cognition, and plasma Alzheimer's biomarkers in moyamoya disease.2023Alzheimer's & dementia : the journal of the Alzheimer's Association
  8. 18F-FDG PET and a classifier algorithm reveal a characteristic glucose metabolic pattern in adult patients with moyamoya disease and vascular cognitive impairment.2023Brain imaging and behavior
  9. Learning spatiotemporal features of DSA using 3D CNN and BiConvGRU for ischemic moyamoya disease detection.2023The International journal of neuroscience
  10. How I do it: superficial temporal artery to middle cerebral artery bypass for moyamoya disease.2022Acta neurochirurgica
  11. A Review of Artificial Intelligence in Cerebrovascular Disease Imaging: Applications and Challenges.2022Current neuropharmacologyFree full text
  12. Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.2022Current neuropharmacologyFree full text
  13. Application of intraoperative electrocorticography in bypass surgery for adult moyamoya disease: a preliminary study.2022Frontiers in bioscience (Landmark edition)
  14. The First 24 h Hemodynamic Management in NICU after Revascularization Surgery in Moyamoya Disease.2021Behavioural neurologyFree full text
  15. Introduction. Translational research advances in the evaluation and management of moyamoya disease.2021Neurosurgical focus
  16. Faded Critical Dynamics in Adult Moyamoya Disease Revealed by EEG and fMRI.2021Oxidative medicine and cellular longevityFree full text
  17. Preliminary Study on the Application of Ultrahigh Field Magnetic Resonance in Moyamoya Disease.2021Oxidative medicine and cellular longevityFree full text
All its trials on ClinicalTrials.gov, any status4
  1. Neurocognitive and Radiological Assessments in Adult Moyamoya Undergoing SurgeryStatus unknownNCT02305407Lead sponsorN/AStart 2016-03
  2. The Adult Hemorrhagic Moyamoya Surgery StudyStatus unknownNCT02319980Lead sponsorPhase 3Start 2015-05
  3. Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya SyndromeRecruitingNCT07894107Study siteStart 2026-08
  4. Registry of Multicenter Brain-Heart Comorbidity in ChinaRecruitingNCT05961748Study siteStart 2012-01
More papers found outside PubMed (not counted)12
  1. Dual-Branch X-CLIP with Feature Purification for Multi-Section DSA Imaging-Based Cerebrovascular Disease Classification2025International Conference on Advanced Algorithms and Neural Networks (AANN)conference-paper
  2. Perioperative management for patients with moyamoya disease: complications’ definition, technical advances, and outcomes2025Research Squarepreprint
  3. 3D DSA-Guided Keyhole STA-MCA Bypass in Moyamoya Vasculopathy2024Springer eBooksbook-chapter
  4. Intraoperative contrast-enhanced ultrasound evaluates the hemodynamic change of cerebral revascularization in adult moyamoya disease: Preliminary results2023WFUMB Ultrasound Openarticle
  5. The Role of Flow-Augmentation Bypass in Moyamoya Disease and Hemodynamic Ischemic Stroke2023Brain and Spinearticle
  6. Analysis of middle cerebral artery blood flow in moyamoya disease and comparison of orthodromic and antidromic bypass2022DOAJ (DOAJ: Directory of Open Access Journals)article
  7. Identification of Vascular Cognitive Impairment in Adult Moyamoya Disease via Integrated Graph Convolutional Network2022Lecture notes in computer scienceconference-paper
  8. Computational Fluid Dynamics Study of Cerebral Revascularization for Moyamoya Disease2021Springer eBooksbook-chapter
  9. Functional Magnetic Resonance Imaging Study of Cerebral Revascularization in Moyamoya Disease2021Springer eBooksbook-chapter
  10. Long-Term Outcome in China2021Springer eBooksbook-chapter
  11. Superficial Temporal Artery-Middle Cerebral Artery Bypass2021Springer eBooksbook-chapter
  12. Superficial Temporal Artery-Middle Cerebral Artery Bypass Combined with Encephalo-Duro-Myo-Synangiosis in Treating Moyamoya Disease2021Springer eBooksbook-chapter

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

9 hospitals in Shanghai for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 7 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 3320232024: 1120242025: 112025

34 hospitals in Shanghai for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led7
  1. Iron dysregulation and ferroptosis are associated with pulmonary fibrosis: Insight from idiopathic pulmonary fibrosis, systemic sclerosis, and COVID-19 patients.2025Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
  2. Icariside II modulates pulmonary fibrosis via PI3K/Akt/β-catenin pathway inhibition of M2 macrophage program.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  3. Pulmonary fibrosis model of mice induced by different administration methods of bleomycin.2023BMC pulmonary medicine
  4. Network pharmacology and experiments in vivo and in vitro reveal that the Jia-Wei-Bu-Shen-Yi-Qi formula (JWBSYQF) and its active ingredient baicalein ameliorate BLM-induced lung fibrosis in mice via PI3K/Akt signaling pathway.2023Journal of ethnopharmacology
  5. Adipose-derived mesenchymal stem cell therapy for reverse bleomycin-induced experimental pulmonary fibrosis.2023Scientific reports
  6. Exploring the comorbidity mechanisms between asthma and idiopathic pulmonary fibrosis and the pharmacological mechanisms of Bu-Shen-Yi-Qi decoction therapy via network pharmacology.2022BMC complementary medicine and therapies
  7. Endocannabinoid signalling/cannabinoid receptor 2 is involved in icariin-mediated protective effects against bleomycin-induced pulmonary fibrosis.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
Earlier papers (2016–2020)1
  1. Clinical Association of Chemokine (C-X-C motif) Ligand 1 (CXCL1) with Interstitial Pneumonia with Autoimmune Features (IPAF).2016Scientific reports

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 10 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 1.3%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 4420232024: 1120242025: 222025

17 hospitals in Shanghai for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Research on Wireless Brain Implant System for General Control of External Devices
    Phase
    N/A
    Started
    2025-03
    Registry
    NCT06829212

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNeurologyRadiology / nuclear medicine
Papers it led10
  1. Prognostic Value of Cerebrospinal Fluid and Serum Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Correlation Study.2025Brain and behavior
  2. Integrated profiling of iPSC-derived motor neurons carrying C9orf72, FUS, TARDBP, or SOD1 mutations.2025Stem cell reports
  3. Inflammation and Brain Structure in Alzheimer's Disease and Other Neurodegenerative Disorders: a Mendelian Randomization Study.2024Molecular neurobiology
  4. Brain region-specific synaptic function of FUS underlies the FTLD-linked behavioural disinhibition.2023Brain : a journal of neurology
  5. A new ERBB4 variant in amyotrophic lateral sclerosis type 19: Case report and review of the literature.2023Clinical neurology and neurosurgery
  6. Iron quantitative analysis of motor combined with bulbar region in M1 cortex may improve diagnosis performance in ALS.2023European radiology
  7. Associations of cardiovascular risk factors and lifestyle behaviors with neurodegenerative disease: a Mendelian randomization study.2023Translational psychiatry
  8. Investigating Casual Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases: A Mendelian Randomization Study.2022Journal of Alzheimer's disease : JAD
  9. The function of FUS in neurodevelopment revealed by the brain and spinal cord organoids.2022Molecular and cellular neurosciences
  10. UNC13A Gene Brings New Hope for ALS Disease-Modifying Drugs.2022Neuroscience bulletin
Earlier papers (2016–2020)10
  1. An exon 5 mutation (c.425G>C, p.Gly141Ala) in the SOD1 gene in a Chinese family associated with incomplete penetrance.2020Amyotrophic lateral sclerosis & frontotemporal degeneration
  2. Familial flail leg ALS caused by PFN1 mutation.2020Journal of neurology, neurosurgery, and psychiatry
  3. Tau Accumulation via Reduced Autophagy Mediates GGGGCC Repeat Expansion-Induced Neurodegeneration in Drosophila Model of ALS.2020Neuroscience bulletin
  4. Amyotrophic lateral sclerosis due to a SOD1 mutation and X-linked recessive bulbospinal neuronopathy in a single family.2019Acta neurologica Belgica
  5. Split-hand phenomenon quantified by the motor unit number index for distinguishing cervical spondylotic amyotrophy from amyotrophic lateral sclerosis.2019Neurophysiologie clinique = Clinical neurophysiology
  6. Radial diffusivity as an imaging biomarker for early diagnosis of non-demented amyotrophic lateral sclerosis.2018European radiology
  7. The investigation of genetic and clinical features in Chinese patients with juvenile amyotrophic lateral sclerosis.2017Clinical genetics
  8. Repetitive nerve stimulation as a diagnostic aid for distinguishing cervical spondylotic amyotrophy from amyotrophic lateral sclerosis.2017European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  9. Compound Muscle Action Potential Decrement to Repetitive Nerve Stimulation Between Hirayama Disease and Amyotrophic Lateral Sclerosis.2017Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
  10. A novel mutation of VAPB in one Chinese familial amyotrophic lateral sclerosis pedigree and its clinical characteristics.2017Journal of neurology
All its trials on ClinicalTrials.gov, any status1
  1. Research on Wireless Brain Implant System for General Control of External DevicesRecruitingNCT06829212Study siteN/AStart 2025-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led 11 of the 55 English-language PubMed papers on spinal muscular atrophy with an author in mainland China, 2021–2025: 20.0%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 2220222023: 5520232024: 1120242025: 002025

6 hospitals in Shanghai for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led11
  1. The clinical characteristics of Hirayama disease in females.2024Neurologia
  2. The role of leisure-time physical activity in maintaining cervical lordosis after anterior cervical fusion and its impact on the motor function in patients with hirayama disease: a retrospective cohort analysis.2023BMC musculoskeletal disorders
  3. Association of joint hypermobility with range of cervical motion and its impact on the motor unit loss in patients with Hirayama disease.2023Muscle & nerve
  4. Loss of cervical sagittal alignment worsens the cervical spinal lesions in patients with Hirayama disease.2023Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  5. Changes in Self-Esteem in Patients with Hirayama Disease and its Association with Prognosis After Anterior Cervical Fusion Procedures.2023World neurosurgery
  6. Efficacy of Anterior Cervical Discectomy and Fusion for Female Patients with Hirayama Disease.2023World neurosurgery
  7. How to reconstruct the lordosis of cervical spine in patients with Hirayama disease? A finite element analysis of biomechanical changes focusing on adjacent segments after anterior cervical discectomy and fusion.2022Journal of orthopaedic surgery and research
  8. Why the patients with Hirayama disease have abnormal cervical sagittal alignment? A radiological measurement analysis of posterior cervical extensors.2022Journal of orthopaedic surgery and research
  9. Teaching NeuroImages: Hirayama Disease With Symmetric Atrophy of Bilateral Distal Upper Extremities.2021Neurology
  10. Quantitative assessment of motor impairment and surgical outcome in Hirayama disease with proximal involvement using motor unit number index.2021Neurophysiologie clinique = Clinical neurophysiology
  11. The Short-Term to Midterm Follow-Up of Patients with Hirayama Disease After Anterior Cervical Discectomy and Fusion.2021World neurosurgery
Earlier papers (2016–2020)14
  1. Establishment of a clinician-led guideline on the diagnosis and treatment of Hirayama disease using a modified Delphi technique.2020Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  2. Analysis of the Effect of Surgical Treatment for the Patients with Hirayama Disease from the Perspective of Cervical Spine Sagittal Alignment.2020World neurosurgery
  3. Snake-Eyes Appearance on MRI Occurs during the Late Stage of Hirayama Disease and Indicates Poor Prognosis.2019BioMed research international
  4. The evaluation on neural status of cervical spinal cord in normal and Hirayama disease using diffusion tensor imaging.2019European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  5. Factors Affecting the Surgical Outcomes of Hirayama Disease: A Retrospective Analysis of Preoperative Magnetic Resonance Imaging Features of the Cervical Spine.2019World neurosurgery
  6. CAN anterior cervical fusion procedures prevent the progression of the natural course of Hirayama disease? An ambispective cohort analysis.2018Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  7. Cortical Activation Changes in Hirayama Disease After Anterior Cervical Decompression and Fusion.2018World neurosurgery
  8. Dynamic Cervical Radiographs in Patients with Hirayama Disease: An Unneglectable Factor on the Choice of Surgery Options.2018World neurosurgery
  9. Changes in the soleus H-reflex test and correlations between its results and dynamic magnetic resonance imaging abnormalities in patients with Hirayama disease.2017Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  10. A double determination of central motor conduction time in the assessment of Hirayama disease.2017Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  11. Motor unit number estimation in the quantitative assessment of severity and progression of motor unit loss in Hirayama disease.2017Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology
  12. Compound Muscle Action Potential Decrement to Repetitive Nerve Stimulation Between Hirayama Disease and Amyotrophic Lateral Sclerosis.2017Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
  13. Risk Factors for Surgical Results of Hirayama Disease: A Retrospective Analysis of a Large Cohort.2017World neurosurgery
  14. A study of dynamic F-waves in juvenile spinal muscular atrophy of the distal upper extremity (Hirayama disease).2016Journal of the neurological sciences
All its trials on ClinicalTrials.gov, any status1
  1. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led 1 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Shanghai for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. High-risk screening for late-onset Pompe disease in China: An expanded multicenter study.2025Journal of inherited metabolic disease
Chinese-language papers (not in the count)1
  1. [Advances in the specific treatments of Pompe disease].2023Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status1
  1. Evaluation of the Safety, Tolerability and Efficacy of Gene Therapy Drug for Late Onset Pompe Disease (LOPD)Not yet recruitingNCT06178432Lead sponsorEarly phase 1Start 2023-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

12 hospitals in Shanghai for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led1
  1. Pseudoexon activating by a deep intronic variant and phenotype variation in a Chinese family with dystrophinopathy.2025Journal of human genetics
All its trials on ClinicalTrials.gov, any status1
  1. A Natural History Study In Chinese Male Patients With Duchenne Muscular DystrophyCompletedNCT03760029Study siteN/AStart 2019-07

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

15 hospitals in Shanghai for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Successful treatment of Behçet's disease ulcers and skin lesions with hydrogen water.2024International journal of dermatology
All its trials on ClinicalTrials.gov, any status1
  1. A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet DiseaseTerminatedNCT04609397Study sitePhase 2Start 2020-11

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 6 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.8%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 3320242025: 002025

26 hospitals in Shanghai for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led6
  1. Renal outcomes in IgA nephropathy following inactivated SARS-CoV-2 vaccination.2024Clinical and experimental nephrology
  2. Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Self-Controlled Study.2024Kidney & blood pressure research
  3. Changes in the spectrum of biopsy-proven renal diseases over 11 years: a single-center study in China.2024Renal failure
  4. Exploring genes for immunoglobulin A nephropathy: a summary data-based mendelian randomization and FUMA analysis.2023BMC medical genomics
  5. Mesangial cell-derived tenascin-C contributes to mesangial cell proliferation and matrix protein production in IgA nephropathy.2022Nephrology (Carlton, Vic.)
  6. KM55 Monoclonal Antibody Staining in IgA-Dominant Infection-Related Glomerulonephritis.2021Nephron
Earlier papers (2016–2020)2
  1. Renal Outcomes of Pregnant Patients with Immunoglobulin A Nephropathy: A Systematic Review and Meta-Analysis.2019American journal of nephrology
  2. Abnormal glucose metabolism and galactose-deficient immunoglobulin A1 (IgA1) synthesis: a possible mechanism of IgA nephropathy.2019Discovery medicine
All its trials on ClinicalTrials.gov, any status3
  1. A Study of SGB-9768 in Patients With Complement-mediated Kidney DiseasesActive, not recruitingNCT06786338Study sitePhase 2Start 2025-06
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

17 hospitals in Shanghai for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Primary biliary cirrhosis degree assessment by acoustic radiation force impulse imaging and hepatic fibrosis indicators.2016World journal of gastroenterology
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Study sitePhase 3Start 2009-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

13 hospitals in Shanghai for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 2 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 3.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led 1 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 3.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Shanghai for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

复旦大学附属华山医院

Huashan Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Huashan Hospital Fudan University; Huashan Hospital & Cancer Metastasis Institute; Huashan Hospital North; Huashan Hospital of Fudan University; Huashan Hospital Affiliated to Fudan University; Fudan University Huashan Hospital; Huashan Hospital Shanghai Medical College; Huashan Hospital and Cancer Metastasis Institute

Suggest a correctionDownload the data